Pheochromocytomas are slow-growing tumors in the adrenal gland. Learn how much they grow each year and how long they take ...

Nineteen (73 per cent) of 26 patients with pheochromocytoma had positive responses to pharmacologic testing with tyramine whereas only three (3 per cent) of 88 patients with other forms of ...

Based on these results, in 2018 the FDA approved iobenguane I-131 as a treatment for adult and paediatric patients 12 years and older with pheochromocytoma and paraganglioma that are positive for ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma ...

The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma should only be initiated if the clinical evidence for the presence of tumor is reasonably ...

b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

Low-osmolar, contrast-enhanced CT can be safely used in patients with pheochromocytoma. “This tool will enhance physicians' abilities to diagnose and treat patients with pheochromocytoma ...

The expanded use would include treatment for patients aged 12 and older who suffer from advanced, unresectable or metastatic pheochromocytoma and paraganglioma, rare tumors that form in and around ...